Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Puff Puff Post

MARCH 10, 2020

InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. It has been fairly slow,” explained Dr. Gallow.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. Beckley Psytech aims to track and improve patient experience through an integrated, digitally-assisted treatment model. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Veriheal

AUGUST 28, 2023

Recent studies have shown that psilocybin may effectively treat patients with obsessive-compulsive disorder (OCD). And it further reinforces the need to carry out clinical trials to determine the safety and efficiency of using psilocybin to treat OCD. In some cases, these patients are prone to depression and suicide.

Treatment 78

Treatment Clinical Trials Therapy Research and Development 78

Canna Care Docs

OCTOBER 3, 2023

On top of overwhelming struggles or feelings, patients who have been diagnosed with a terminal illness can face a broad range of both physical and psychological effects. Some patients diagnosed with a terminal illness may begin to feel depressed or physically and mentally lethargic from the effects and symptoms of their disease.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JUNE 21, 2021

In the medical cannabis industry, mostly due to the plant’s long history of prohibition, there is a decided lack of data regarding the use and efficacy of cannabis as a treatment for a wide variety of indications. The most recent one , from June 2021, takes a look at patients using cannabis to relieve pain.

Data 105

Data Clinical Trials Research and Development Indica 105

TheAnswerPage

JANUARY 11, 2022

Are you able to answer your patients’ medical marijuana questions? Also, a recent systematic review of healthcare professionals’ “cannabis knowledge” reported “there was a unanimous lack of self-perceived knowledge surrounding all aspects of medicinal cannabis” (2). million medical marijuana patients nationwide.

Patients 98

Patients Education Marijuana Therapy 98

MMJ Recs

NOVEMBER 30, 2023

While traditional treatments like antiepileptic drugs exist, they may not always provide adequate relief for all patients. Medical Marijuana for Epilepsy Treatment Medical marijuana, often referred to as MMJ, is a term used to describe the use of cannabis and its derivatives for therapeutic purposes.

Epilepsy 105

Epilepsy Treatment Patients Strains 105

Cannabis Law Report

AUGUST 17, 2021

reduction in 28-day seizure frequency relative to baseline in tuberous sclerosis complex (TSC) patients (n=23). Secondary endpoint of 50% responder rate at 30.4%, consistent with the Marigold Phase 3 CDKL5 deficiency disorder trial results. reduction was observed in focal seizures (n=19), the most common seizure type in TSC patients.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

DECEMBER 7, 2021

Despite the increased use of medical cannabinoids, the efficacy and safety of the treatment among children remain uncertain. The objective was to study the efficacy and safety of medical cannabinoids in children. Eight studies were included, all of which are randomized controlled trials. 1.69, 95% CI [1.20–2.36])

Safety 52

Safety Cannabinoids Events Data 52

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Fortunately, the U.S. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

MMJ Recs

NOVEMBER 20, 2023

This article delves into the science behind medical marijuana, focusing on cannabinoids, the active compounds found in the cannabis plant, and their remarkable therapeutic effects. THC is the primary psychoactive compound in cannabis, responsible for the “high” or euphoric feeling associated with marijuana use.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

Cannabis Law Report

JULY 29, 2021

OTTAWA, ON , July 29, 2021 /PRNewswire/ – Tetra Bio-Pharma Inc (“Tetra” or the Company”) (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and development has announced that it filed a PCT patent application for Cannabis Plant Residue and Use Thereof, PCT Patent Application No.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

MMJ Recs

DECEMBER 28, 2023

As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Medicinal Marijuana Association

FEBRUARY 11, 2024

You may have heard whispers of cannabis being used to address a specific eye condition, but what does the research truly reveal about its effectiveness? The potential link between cannabis and glaucoma treatment is a topic of ongoing investigation, stirring both curiosity and caution within the medical community.

Treatment 52

Treatment Blood Pressure Conditions Clinical Trials 52

NORML

JANUARY 4, 2019

Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis. Pennsylvania.

Legislation 125

Legislation Clinical Trials Research and Development Access 125

Cannabis Law Report

JUNE 4, 2021

– Drug Demonstrates Efficacy and Safety in Advanced Prostate Cancer Patients. – Phase 2 Trial Underway. Highlights from the presentation include: Declining PSA levels in treated patients. Declining circulating tumor cell (CTC) count in treated patients. Phase 2 trial underway. AIkido Pharma Inc.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. “Patients will benefit from cGMP-quality therapies in an accessible and efficient format.”. .

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

AUGUST 31, 2021

Barely a quarter of cannabis users trust their doctor to provide them with reliable information about medical cannabis and how to use it to treat their medical or health conditions, according to a recent survey. People want to trust their doctors, but doctors need knowledge. We have a ways to go,” Tan said.

Education 101

Education Clinical Trials Medicine Policy 101

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

AUGUST 21, 2019

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

CannaMD

SEPTEMBER 28, 2020

Patients around the world are reporting a sharp increase in sleep problems, and physicians have coined the term coronasomnia to describe the phenomenon. Many physicians turn to pharmacologic interventions to help patients sleep. However, there is a tradeoff between effectiveness and safety. Is there a more natural remedy?

Sleep 73

Sleep Clinical Trials Patients THC 73

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

JULY 30, 2019

Cannabis-based products will be allowed to bypass usual processes required for medicines in New Zealand and go directly onto the market without any proof of safety or effectiveness. This unprecedented proposal is contained in the government’s consultation document on giving greater access to medicinal cannabis.

Medicine 40

Medicine Clinical Trials Safety Access 40

Cannabis Law Report

AUGUST 12, 2021

11, 2021 (GLOBE NEWSWIRE) COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2021 and gave an update on recent progress across its business. LONDON, Aug. Business highlights.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Cannabis Law Report

JANUARY 31, 2022

The SAP is a federal program that allows healthcare professionals to apply for access to non-marketed medications that have not yet been approved for sale, when such medications show clinical evidence of safety and efficacy and are intended to treat patients with a severe or life-threatening illness.

Research and Development 52

Research and Development Clinical Trials Packaging Access 52

WeedAdvisor

JULY 4, 2019

Despite mounting evidence into cannabis’ therapeutic benefits, the DEA continues to close its eyes and plug its ears, constantly claiming that there is not enough research to support its medicinal value, according to Marijuana Moment. It could be argued that the DEA is hesitant for the sake of public safety. A Vicious Circle. .

DEA 111

DEA Research and Development Clinical Trials Cultivation 111

Cannabis Law Report

OCTOBER 15, 2021

DNA variations or polymorphisms) in patients with African ancestry. The KGA is a proprietary computational platform built in-house at Goldfinch Bio to identify genetic and environmental causes of kidney diseases in patient subsets and the associated biological targets for therapeutic intervention. Poster Number: INFO37.

Clinical Trials 52

Clinical Trials Research and Development Data Patients 52

The Cannigma

JULY 1, 2022

There’s no doubt that the amount of information that is available about cannabis is at an all-time high – in 2020 alone, over 3,500 scientific articles were published on the topic. These claims influence things like how consumers purchase cannabis or how doctors consult with medical cannabis patients.

Research and Development 108

Research and Development Data THC Clinical Trials 108